JP7897576B2 - がんの治療に有用なモレファンチン誘導体 - Google Patents

がんの治療に有用なモレファンチン誘導体

Info

Publication number
JP7897576B2
JP7897576B2 JP2023566885A JP2023566885A JP7897576B2 JP 7897576 B2 JP7897576 B2 JP 7897576B2 JP 2023566885 A JP2023566885 A JP 2023566885A JP 2023566885 A JP2023566885 A JP 2023566885A JP 7897576 B2 JP7897576 B2 JP 7897576B2
Authority
JP
Japan
Prior art keywords
cancer
compound
formula
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023566885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517443A (ja
JP2024517443A5 (cg-RX-API-DMAC7.html
Inventor
ヨン リィ,ホイ
俊介 千葉
クアン ライ,ソーク
ジー コー,チョン
ワー ローランド オン,トゥーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanyang Biologics Pte Ltd
Original Assignee
Nanyang Biologics Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanyang Biologics Pte Ltd filed Critical Nanyang Biologics Pte Ltd
Publication of JP2024517443A publication Critical patent/JP2024517443A/ja
Publication of JP2024517443A5 publication Critical patent/JP2024517443A5/ja
Application granted granted Critical
Publication of JP7897576B2 publication Critical patent/JP7897576B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023566885A 2021-04-29 2022-04-27 がんの治療に有用なモレファンチン誘導体 Active JP7897576B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202104429U 2021-04-29
SG10202104429U 2021-04-29
PCT/SG2022/050251 WO2022231520A1 (en) 2021-04-29 2022-04-27 Molephantin derivatives useful in the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2024517443A JP2024517443A (ja) 2024-04-22
JP2024517443A5 JP2024517443A5 (cg-RX-API-DMAC7.html) 2025-06-11
JP7897576B2 true JP7897576B2 (ja) 2026-07-30

Family

ID=83848883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566885A Active JP7897576B2 (ja) 2021-04-29 2022-04-27 がんの治療に有用なモレファンチン誘導体

Country Status (7)

Country Link
US (1) US20250304544A1 (cg-RX-API-DMAC7.html)
EP (1) EP4330241A4 (cg-RX-API-DMAC7.html)
JP (1) JP7897576B2 (cg-RX-API-DMAC7.html)
CN (1) CN117377663A (cg-RX-API-DMAC7.html)
AU (1) AU2022265461A1 (cg-RX-API-DMAC7.html)
IL (1) IL308058A (cg-RX-API-DMAC7.html)
WO (1) WO2022231520A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115919833A (zh) * 2023-01-31 2023-04-07 暨南大学附属第一医院(广州华侨医院) 一种CutC蛋白抑制剂及其应用
AU2024337402A1 (en) * 2023-09-06 2026-03-26 Nanyang Biologics Pte. Ltd. Collective synthesis of phantomolin family through total synthesis of the sesquiterpene lactone molephantin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040335A1 (en) 2017-08-19 2019-02-28 University Of Rochester MICHELOLID DERIVATIVES, PREPARATION METHODS AND THEIR USE AS ANTICANCER AND ANTI-INFLAMMATORY AGENTS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3418724B2 (ja) * 2000-02-10 2003-06-23 国立医薬品食品衛生研究所長 セスキテルペノイド化合物及びそれを含む医薬
JP2005002050A (ja) * 2003-06-12 2005-01-06 Shiseido Co Ltd 美白剤及びこれを配合した皮膚外用剤
CN102000072A (zh) * 2009-09-01 2011-04-06 奇复康药物研发(苏州)有限公司 偶联有一氧化氮供体的抗肿瘤天然药物及其医药用途
CN103732586B (zh) * 2011-04-07 2016-02-03 南洋理工大学 作为抗癌剂的乙酰基丹参酮iia(ata)
CN111153910B (zh) * 2020-01-09 2021-07-30 沈阳药科大学 地胆草种内酯衍生物及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040335A1 (en) 2017-08-19 2019-02-28 University Of Rochester MICHELOLID DERIVATIVES, PREPARATION METHODS AND THEIR USE AS ANTICANCER AND ANTI-INFLAMMATORY AGENTS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lee, Kuo-Hsiung; Ibuka, Toshiro; Furukawa, Hiroshi; Kozuka, Mutsuo; Wu, Rong-Yang; Hall, Iris H.; Huang, Huan-Chang,Antitumor agents. XXXVIII: Isolation and structural elucidation of novel germacranolides and triterpenes from Elephantopus mollis,Journal of Pharmaceutical Sciences,1980年,69(9),pp.1050-1056,CODEN: JPMSAE; ISSN: 0022-3549, DOI 10.1002/jps.2600690917

Also Published As

Publication number Publication date
US20250304544A1 (en) 2025-10-02
IL308058A (en) 2023-12-01
AU2022265461A1 (en) 2023-11-16
JP2024517443A (ja) 2024-04-22
CN117377663A (zh) 2024-01-09
EP4330241A1 (en) 2024-03-06
WO2022231520A1 (en) 2022-11-03
EP4330241A4 (en) 2025-03-19

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250418

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260708

R150 Certificate of patent or registration of utility model

Ref document number: 7897576

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150